Skip to main content

Table 1 Patient and donor characteristics in the retrospective study

From: Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis

Characteristics

All patients

MSDT

 

HBMT

 

MRDneg

MRDpos

MRDneg

MRDpos

Number of patients

339

85

14

 

189

51

 

Median age (range), years

31 (2–60)

41 (12–57)

44 (5–57)

0.457

27 (2–60)

28 (9–57)

0.151

Weight (range), kg

61 (15.5–118)

66.5 (29–97)

68 (23–96)

1.000

64 (15.5–118)

60 (25–102)

0.286

Male, n (%)

165 (48.7%)

41 (48.2%)

9 (64.3%)

0.263

96 (50.8%)

19 (37.3%)

0.086

Diagnosis, n (%)

   

0.264

  

0.031

 De novo AML

333 (98.2%)

84 (98.8%)

13 (92.9%)

 

188 (99.5%)

48 (94.1%)

 

 Secondary AML

6 (1.8%)

1 (1.2%)

1 (7.1%)

 

1 (0.5%)

3 (5.9%)

 

Disease status, n (%)

   

0.217

  

0.137

 CR1

301 (88.8%)

81 (95.3%)

12 (85.7%)

 

167 (88.4%)

41 (80.4%)

 

 CR > 1

38 (11.2%)

4 (4.7%)

1 (14.3%)

 

22 (11.6%)

10 (19.6%)

 

FLT3-ITD mutation

   

0.302

  

0.582

 Yes

20 (5.9%)

5 (5.9%)

2 (14.3%)

 

11 (5.8%)

2 (3.9%)

 

 No

319 (94.1%)

80 (94.1%)

12 (85.7%)

 

178 (94.2%)

49 (96.1%)

 

Cytogenetics

   

0.247

  

0.285

 Favorable

59 (17.4%)

16 (18.8%)

1 (7.1%)

 

30 (15.9%)

12 (23.5%)

 

 Intermediate

263 (77.6%)

65 (76.5%)

13 (92.9%)

 

150 (79.4%)

35 (68.6%)

 

 Adverse

17 (5.0%)

4 (4.7%)

0

 

9 (4.8%)

4 (7.8%)

 

Conditioning regimen, n (%)

 MA

339 (100%)

85 (100%)

14 (100%)

 

189 (100%)

51 (100%)

 

HLA-A-, B-, and DR-mismatched grafts, n (%)

      

0.245

 0

101 (29.8%)

85 (100%)

14 (100%)

 

1 (0.5%)

1 (2.0%)

 

 1

14 (4.1%)

0

0

 

13 (6.9%)

1 (2.0%)

 

 2

55 (16.2%)

0

0

 

40 (21.2%)

15 (29.4%)

 

 3

126 (49.9%)

0

0

 

135 (71.4%)

34 (66.7%)

 

Donor-recipient sex-matched grafts, n (%)

   

0.249

  

0.481

 Male–male

104 (30.7%)

22 (25.9%)

4 (28.6%)

 

62 (32.8%)

16 (31.4%)

 

 Male–female

86 (25.3%)

25 (29.4%)

1 (7.1%)

 

55 (29.1%)

14 (27.5%)

 

 Female–male

95 (28.0%)

32 (37.6%)

8 (57.1%)

 

44 (23.3%)

8 (17.6%)

 

 Female–female

47 (13.9%)

6 (7.1%)

1 (7.1%)

 

28 (14.8%)

12 (23.5%)

 

Donor-recipient relationship, n (%)

      

0.439

 Parent–child

128 (37.8%)

0

0

 

104 (55.0%)

24 (47.1%)

 

 Sibling–sibling

176 (51.9%)

85 (100%)

14 (100%)

 

58 (30.7%)

19 (37.3%)

 

 Child–parent

32 (9.4%)

0

0

 

24 (12.7%)

8 (15.7%)

 

 Other

3 (0.9%)

0

0

 

3 (1.6%)

0 (0%)

 

ABO matched grafts, n (%)

      

0.087

 Matched

201 (59.3%)

53 (62.4%)

9 (64.3%)

0.345

104 (55.0%)

35 (68.6%)

 

 Major mismatch

62 (18.3%)

19 (22.4%)

1 (7.1%)

 

39 (20.6%)

3 (5.9%)

 

 Minor mismatch

58 (17.1%)

9 (10.6%)

2 (14.3%)

 

36 (19.0%)

11 (21.6%)

 

 Bi-directional mismatch

18 (5.3%)

4 (4.7%)

2 (14.3%)

 

10 (5.3%)

2 (3.9%)

 

EBMT score, n (%)

   

0.063

  

0.850

 0

0

0

0

 

0

0

 

 1

73 (21.5%)

23 (27.1%)

3 (21.4%)

 

38 (20.1%)

9 (17.6%)

 

 2

156 (46.0%)

50 (58.8%)

7 (50.0%)

 

78 (41.3%)

21 (41.2%)

 

 3

76 (22.4%)

11 (12.9%)

1 (7.1%)

 

50 (26.5%)

14 (27.5%)

 

 4

25 (7.4%)

1 (1.2%)

2 (14.2%)

 

18 (9.5%)

4 (7.8%)

 

 5

9 (2.7%)

0

1 (7.1%)

 

5 (2.6%)

3 (5.9%)

 

Cell compositions in allografts

 Infused nuclear cells, (range) 108/kg

7.51 (3.98–16.77)

7.51 (3.98–14.75)(5.18–14.93)

7.12 (5.78–12.75)

0.896

7.40 (4.32–16.77)

7.69 (5.4–14.07)

0.262

 Infused CD34+ cells, (range) 106/kg

2.32 (0.50–9.78)

2.26 (0.76–9.78)

2.05 (1.16–5.04)

0.670

2.32 (0.50–9.47)

2.46 (1.04–8.80)

0.448

DLI after transplant, n (%)

 For relapse prophylaxis and intervention

28 (8.3%)

6 (7.1%)

4 (28.6%)

0.046

13 (6.9%)

5 (9.8%)

0.686

 For relapse treatment

19 (5.6%)

2 (2.4%)

2 (14.3%)

0.171

12 (6.3%)

3 (5.9%)

0.902

  1. Abbreviations: HLA human leukocyte antigen, MSDT HLA-matched sibling donor transplantation, HBMT unmanipulated haploidentical blood and marrow transplantation, MRD minimal residual disease, neg negative, pos positive, AML acute myeloid leukemia, CR complete remission, MA myeloablative regimen, EBMT European Group for Blood and Marrow Transplantation, DLI donor lymphocyte infusions